INTRODUCTION
Atherosclerosis is a chronic disease characterized by accumulation of fat and cholesterol in the arterial wall leading to restriction of blood flow [1] [2] [3] . Atherosclerotic plaques contain a number of cell types including smooth muscle cells (SMCs), macrophages, endothelial cells, B cells, T cells, and fibroblasts, among others [4] [5] [6] [7] [8] . Recent lineage tracing studies provide strong evidence that a substantial proportion of cells in the plaque are derived from the endothelium. This process, referred to as endothelial-to-mesenchymal transition (EndMT) is characterized by the loss of normal endothelial and gain of mesenchymal fate markers. Functional consequences include deposition of proinflammatory extracellular matrix, facilitation of recruitment of leukocytes, and growth of unstable plaque. Here, we review the current understanding of molecular controls of EndMT and its contribution to the development of atherosclerosis.
ATHEROSCLEROSIS
Atherosclerosis is best viewed as a chronic, progressive inflammatory disease. The slow evolution of atherosclerotic lesions combines endothelial dysfunction with recruitment of leukocytes, extensive lipid deposition, proliferation of medial SMCs, and remodeling of the extracellular matrix. Endothelial cells play a critical role in the development of atherosclerosis. The normal endothelium is involved in multiple aspects of vascular physiology including regulation of vascular barrier function, leukocyte trafficking, thrombosis prevention, and regulation of vascular tone. Endothelial dysfunction is an important step in the development and progression of atherosclerotic lesions and its occurrence has been considered a predictor of subsequent development of atherosclerosis. Most atherosclerosis triggers, including both mechanical and local inflammatory factors, can activate the endothelium, resulting in expression of chemokines and cytokines [e.g., interleukin (IL)-1, IL-6, IL-8, monocyte chemoattractant protein-1) and adhesion receptors (e.g., Intercellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Molecule 1 (VCAM-1), Endothelial-leukocyte Adhesion Molecule 1 (E-selectin)] that attract and facilitate immune cell extravasation [9] .
ENDOTHELIAL-TO-MESENCHYMAL TRANSITION
Recent studies have demonstrated that endothelial cells exhibit a high degree of organ heterogeneity and plasticity both in physiologic and pathologic settings. Endothelial plasticity can range from a subtle shift from quiescent to activated state to a full-blown fate change characterized by a nearly complete loss of endothelial and acquisition of mesenchymal, fate markers. The latter process, termed EndMT, is not necessarily pathologic. Indeed, EndMT is critical-to-normal embryogenesis, most notably in developing cardiac valves. During valve morphogenesis, EndMT is responsible for of endocardial cells of the atrioventricular canal into mesenchymal cells that populate atrioventricular cushions and subsequently give rise to the mitral and tricuspid valves [10] . EndMT is also involved in generation of cardiac fibroblasts and formation of intracardiac septa [11] . Although some degree of EndMT in adult tissues may be a normal component of wound healing/injury recovery response, prolonged and/or extensive EndMT is clearly pathologic [12 & ]. Various studies demonstrated its occurrence in a number of disease settings including organ fibrosis [13, 14, 15 && ], restenosis [16] , transplant arteriopathy [17] , vein graft remodeling [18] , pulmonary hypertension [19] , and cancer [20] .
More recently, EndMT has been shown to be an important contributor to atherosclerosis, both in mouse models and in patients [ Abnormal shear stress occurring in certain segments of the arterial vasculature has long been known to be responsible for the preponderance of atherosclerotic lesions in these locations via its effect on luminal endothelial cells [25] . Low shear stress promotes, whereas high shear stress suppresses, vascular inflammation and thrombosis. More recently, shear stress has been linked to EndMT with uniform laminar shear stress inhibiting EndMT development via activation of extracellularsignal-regulated kinase 5 (ERK5) signaling, and disturbed flow promoting it [21] . Low shear stressdependent stimulation of may involve upregulation of expression of twist-related protein 1 and Snail transcription factors [26,27 & ].
The HDL-cholesterol fraction, which has been associated with antiatherosclerotic effects, reduces transforming growth factor beta 1 (TGFb1)-induced EndMT via upregulation of the inhibitor Smad (Smad7) and decreases expression of EndMT transcription factors Slug and zinc finger e-box binding homeobox 1 (ZEB1) [28] . Furthermore, the lipoprotein Apolipoprotein A1/ATP Binding Cassette Subfamily A member 1 inhibits TGFb1-induced EndMT through repression of the TGFb1/Smad2/Smad3/ Snail/Slug pathway in human coronary artery endothelial cells [29] .
SIGNALING PATHWAYS REGULATING ENDOTHELIAL-TO-MESENCHYMAL TRANSITION

Fibroblast growth factor signaling pathway
The 22 fibroblast growth factors (FGFs) family members signal via four plasma membrane tyrosine kinase receptors (FGFR1-4). In the vasculature, FGF signaling is involved in numerous biological processes including modulation of angiogenesis, maintenance of vascular integrity, and regulation of endothelial cell identity [30, 31] . Binding of an FGF ligand to an FGFR induces the latter to dimerize and transphosphorylate-specific tyrosine residues in its cytoplasmic kinase domains thereby leading to KEY POINTS FGF-TGFb cross-talk is a nearly universal phenomenon.
TGFb signaling activates EndMT.
Prolonged EndMT is deleterious and drives disease progression in a number of settings.
its activation [32] . Subsequent phosphorylation events in the receptor cytoplasmic domains and a constitutively docked adaptor protein FGF receptor substrate 2 alpha (FRS2a) generate docking sites for numerous cytoplasmic proteins. This, in turn, results in activation of downstream signaling cascades including Ras/mitogen-activating protein kinase (MAPK), phosphoinositide-3-kinase (PI3K)/ Akt pathway, and phospholipase C gamma pathways [33] .
All FGF receptors (FGFR1-4), the adaptor protein FRS2a, and their coreceptor Klotho and Syndecan-4 have been genetically knocked out in mice [34] [35] [36] [37] [38] [39] [40] [41] . However, these global knockout phenotypes are not very informative with regard to vascular development either due to very early embryonic lethality occurring prior to critical stages of blood vessel development (i.e., Fgfr1 À/À ) or the absence of a phenotype due to compensation by other FGFRs. More detailed insights in the role of FGF signaling in the endothelium emerged from cell-type specific knockouts of FGF receptors. A conditional endothelial-specific knockout of Fgfr1 and Fgfr2 showed that mice are viable with no vascular developmental defects [42] . However, there was a significant impairment of angiogenic response after eye injury and delayed skin wound healing in adult mice. At the same time, an endothelial-specific knockout of Fgfr1 in combination with a global Fgfr3 knockout resulted in impaired development of blood and lymphatic vessels [43] . Significantly, an endothelial-specific knockout of either Fgfr1 or Frs2a increased neointima formation in transplant arteriopathy and atherosclerosis models due to induction of EndMT [17, 22 && ]. Finally, FGF signaling also plays an important role in the maintenance of vascular endothelial growth factor receptor 2 (VEGFR2) expression and is required for the maintenance of both blood and lymphatic endothelial cell identity through FGF-Ras-MAPK signaling [31, [44] [45] [46] .
Transforming growth factor beta signaling pathway
TGFb, a member of the TGF superfamily of growth factors, has been reported to be involved in a wide range of diverse and often contradictory functions. It plays important roles both in physiological (embryonic development, differentiation, cell growth, cell death, tissue homeostasis) and pathological processes (autoimmunity, inflammation, fibrosis, angiogenesis, oncogenesis, and cardiovascular disease) [47] . The three TGFb isoforms (TGFb1, TGFb2, and TGFb3) signal through two types of serine/threonine kinase receptors called types I and II TGFb receptors [48] . Once dimerized by ligand binding these protein complexes trigger signal transduction by phosphorylation of their specific receptor-regulated Smads (R-Smads2 and 3). Activated R-Smads interact with the common partner Smad, Smad4, and accumulate in the nucleus where the Smad complex directly binds to defined elements on the DNA and regulates target gene expression together with other factors [49, 50] . In addition to activating the canonical Smad signaling pathway, TGFb signaling can also activate noncanonical cascades including PI3K/AKT, MAPK, and Rho-like GTPase signaling pathways [51, 52] . However, the relationship between TGFb signaling and non-Smad activation has been poorly understood. The type III TGFb receptors, betaglycan and endoglin, function as ligand reservoirs, holding ligands close to the cell surface in a manner analogous to the role played by heparan sulfate proteoglycans in FGF signaling [53] .
In vitro, TGFb has been shown to inhibit endothelial cell proliferation and migration and to stimulate smooth muscle and mesenchymal cell differentiation and extracellular matrix accumulation [54] [55] [56] . TGFb signaling in endothelial cells is essential for precise regulation of blood vessel assembly, normal embryonic development, postnatal angiogenesis, and homeostasis maintenance in the adult vasculature. When induced early, endothelial cell-specific knockouts of Tgfbr1 or Tgfbr2 result in embryonic lethality at $E10.5 with extensive yolk sac vascular network defects [57] . Endothelial-specific excision activation of Tgfbr2 at E11.5 leads to abnormal ventricular septation and cerebral hemorrhage [58] . Finally, endothelial Tgfbr2 excision at the postnatal day 2 results in angiogenic defects in the retina [59] . Extensive studies also showed that TGFb promotes SMC differentiation and stimulates SMC marker gene expression through Smad2/Smad3 activation [60] [61] [62] . Selective deletion of Tgfbr1 or Tgfbr2 in SMCs causes embryonic lethality due to vascular deformities [57] . Adult mice lacking Tgfbr2 in vascular smooth muscle cells (VSMCs) also show vascular defects including increased VSMC proliferation, decreased smooth muscle contractile markers, and exhib aortic thickening, dilatation, and dissection [52] .
FIBROBLAST GROWTH FACTOR-TRANSFORMING GROWTH FACTOR BETA CROSS-TALK
As already outlined, FGF and TGFb signaling pathways play important roles in regulating endothelial and SMC behaviors. However, the two signaling systems often have diametrically opposite effects. For example, FGFs induces SMC proliferation, whereas TGFb inhibits it [56, 63] . Although it has been appreciated for some time that these signaling cascades can influence and counteract each other, little was known about the molecular details of these interactions until recently. Early in-vitro studies showed that FGF2 inhibits TGFbR1 expression [64] . It also antagonizes TGFb-mediated induction of SMC markers expression in pericytes and SMCs [65] and can revert TGFb-induced epithelial-to-mesenchymal transition [66] . More recent studies showed that inhibition of FGF signaling in the endothelium induced by Fgfr1 or Frs2a deletion results in increased TGFb signaling leading to EndMT [17, 67] . The molecular basis of this crosstalk proved rather unusual. FGF signaling input is required for maintenance of let-7 miRNA expression. Both TGFbR1 and Smad2 three prime untranslated region (3'-UTR) contain multiple let-7 binding sites; let-7 binding to these sites results in reduction in these mRNAs levels. A decrease in FGF signaling input leads to a 20-120 decline in let-7 levels. This, in turn, markedly prolongs TGFbR1 (and Smad2) mRNA half-lives, thus increasing their protein expression and allowing activation of TGFb signaling [17] .
The effect of FGF signaling shutdown is not limited to TGFbR1 as expression of all TGFb receptors is increased as is the expression of TGFb ligands, with TGFb2 demonstrating the biggest increase [17] . Whether all of these TGFb family members' expression is also directly regulated by let-7 or is due to something else, has not been established. Although initially described in endothelial cells, the FGF-let-7-TGFb cross-talk appears to be quite universal, having also been observed in SMCs and fibroblasts [56] .
Fibroblast growth factor-transforming growth factor beta cross-talk in endothelial cells
Although FGF regulation of TGFb signaling appears to be pretty universal, functional consequences of this cross-talk are quite different for different cell types. It is particularly instructive to construct biological consequences of extinguishing FGF signaling and activating TGFb signaling in endothelial vs. SMCs. In vitro, endothelial cells treated with TGFb undergo EndMT as demonstrated by changes in cell shape, loss of endothelial cell markers, and gain mesenchymal marker gene expression. A dominant-negative form of Smad4, the TGFbR1 kinase inhibitor SB431542, and the TGFb antagonist bone morphogenetic protein 7 (BMP7) all block TGFbinduced EndMT [13] . In agreement with these data, in-vivo studies confirmed the central role played by activation of endothelial TGFb signaling in EndMT induction including both in development [68] and disease settings [17,22 && ]. Like these in-vitro observations, EndMT in blood vessels results in endothelial cells losing their highly differentiated state, becoming proliferative, and acquiring mesenchymal characteristics. This, in turn, promotes disease processes such as atherosclerosis [22 && ].
Fibroblast growth factor-transforming growth factor beta cross-talk in smooth muscle cells
As in endothelial cells, there is strong evidence linking FGF signaling in SMCs to suppression of TGFb signaling and the loss of FGF signaling input to activation of TGFb signaling output. However, biological consequences are very different. FGF2 is a potent SMC mitogen and a powerful inducer of the SMC contractile-to-proliferative phenotype switch [63] . The induction of a proliferative phenotype is characterized by the loss of normal contractile protein expression, appearance of nonmuscle isoforms of muscle proteins, secretion of extracellular matrix, and increased proliferative and migratory behavior.
In vivo, this is commonly observed in injury settings when local FGF release leads to contractile-to-proliferative phenotype transition. The end result is a marked increase in medial SMC proliferation and neointima formation, features of several common diseases including atherosclerosis and restenosis [69, 70] . In contrast to FGF, TGFb promotes SMC differentiation and converts proliferative SMCs back to contractile state [63] . In-vivo activation of SMC TGFb signaling induced by the loss of FGF signaling input, engineered by an SMC-specific Frs2a deletion, results in markedly reduced neointima lesion development in both atherosclerosis and carotid artery ligation models [56, 63] . Thus, the loss of FGF signaling in both the endothelium and SMCs activates TGFb signaling. In the endothelium, this leads to the loss of cell differentiation, transition to an undifferentiated state and leads to promotion of diseases such as atherosclerosis. In contrast, in SMCs, the same process shifts undifferentiated cells to the differentiated phenotype and suppresses atherosclerotic progression (Fig. 1) .
CONCLUSION
FGF-TGFb cross-talk, an increase in TGFb signaling in response to declining FGF signaling input, is a nearly universal biological occurrence. Yet despite common underlying molecular mechanisms of this cross-talk, its biological defects are very different depending on the time of occurrence and specific cell type involved. It's critical-to-normal cardiac development and plays an important role in limiting tissue injury and promoting repair. On the other hand, a chronic persistence of EndMT leads to a number of adverse pathological consequences and may play a key role in the development and growth of atherosclerotic lesions.
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Papers of particular interest, published within the annual period of review, have been highlighted as: FIGURE 1. Fibroblast growth factor-transforming growth factor beta signaling antagonizing in endothelial cells and smooth muscle cells. In both endothelial cells and smooth muscle cells, inhibition of fibroblast growth factor signaling leads to upregulation of transforming growth factor beta signaling activity; however, the biological outcome of this cross-talk are completely different in each cell type. In endothelial cell (a), activation of transforming growth factor beta signaling cascade induces endothelial cell to mesenchymal transition, increases inflammation, permeability, and extracellular matrix deposition, thereby accelerating atherosclerosis. In smooth muscle cell (b), activation of transforming growth factor beta signaling cascade promotes differentiation/maturation, maintains vascular homeostasis, and increases extracellular matrix deposition, thereby inhibiting the progression of atherosclerosis [22 && ,56].
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